Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues

Saeid Zanganeh, Gregor Hutter, Ryan Spitler, Olga Lenkov, Morteza Mahmoudi, Aubie Shaw, Jukka Sakari Pajarinen, Hossein Nejadnik, Stuart Goodman, Michael Moseley, Lisa Coussens, Heike Elisabeth Daldrup-Link

Research output: Contribution to journalArticle

287 Citations (Scopus)

Abstract

Until now, the Food and Drug Administration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been used for treating iron deficiency, as contrast agents for magnetic resonance imaging and as drug carriers. Here, we show an intrinsic therapeutic effect of ferumoxytol on the growth of early mammary cancers, and lung cancer metastases in liver and lungs. In vitro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 activity. Macrophages exposed to ferumoxytol displayed increased mRNA associated with pro-inflammatory Th1-type responses. In vivo, ferumoxytol significantly inhibited growth of subcutaneous adenocarcinomas in mice. In addition, intravenous ferumoxytol treatment before intravenous tumour cell challenge prevented development of liver metastasis. Fluorescence-activated cell sorting (FACS) and histopathology studies showed that the observed tumour growth inhibition was accompanied by increased presence of pro-inflammatory M1 macrophages in the tumour tissues. Our results suggest that ferumoxytol could be applied â € off label' to protect the liver from metastatic seeds and potentiate macrophage-modulating cancer immunotherapies.

Original languageEnglish (US)
Pages (from-to)986-994
Number of pages9
JournalNature Nanotechnology
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Ferrosoferric Oxide
macrophages
Macrophages
Iron oxides
iron oxides
Tumors
tumors
liver
Liver
Polarization
Tissue
Nanoparticles
nanoparticles
cancer
metastasis
polarization
lungs
Cells
Iron
iron

ASJC Scopus subject areas

  • Bioengineering
  • Atomic and Molecular Physics, and Optics
  • Biomedical Engineering
  • Materials Science(all)
  • Condensed Matter Physics
  • Electrical and Electronic Engineering

Cite this

Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., ... Daldrup-Link, H. E. (2016). Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nature Nanotechnology, 11(11), 986-994. https://doi.org/10.1038/nnano.2016.168

Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. / Zanganeh, Saeid; Hutter, Gregor; Spitler, Ryan; Lenkov, Olga; Mahmoudi, Morteza; Shaw, Aubie; Pajarinen, Jukka Sakari; Nejadnik, Hossein; Goodman, Stuart; Moseley, Michael; Coussens, Lisa; Daldrup-Link, Heike Elisabeth.

In: Nature Nanotechnology, Vol. 11, No. 11, 01.11.2016, p. 986-994.

Research output: Contribution to journalArticle

Zanganeh, S, Hutter, G, Spitler, R, Lenkov, O, Mahmoudi, M, Shaw, A, Pajarinen, JS, Nejadnik, H, Goodman, S, Moseley, M, Coussens, L & Daldrup-Link, HE 2016, 'Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues', Nature Nanotechnology, vol. 11, no. 11, pp. 986-994. https://doi.org/10.1038/nnano.2016.168
Zanganeh, Saeid ; Hutter, Gregor ; Spitler, Ryan ; Lenkov, Olga ; Mahmoudi, Morteza ; Shaw, Aubie ; Pajarinen, Jukka Sakari ; Nejadnik, Hossein ; Goodman, Stuart ; Moseley, Michael ; Coussens, Lisa ; Daldrup-Link, Heike Elisabeth. / Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. In: Nature Nanotechnology. 2016 ; Vol. 11, No. 11. pp. 986-994.
@article{c1fa72348d0f47789db90f623578f0de,
title = "Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues",
abstract = "Until now, the Food and Drug Administration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been used for treating iron deficiency, as contrast agents for magnetic resonance imaging and as drug carriers. Here, we show an intrinsic therapeutic effect of ferumoxytol on the growth of early mammary cancers, and lung cancer metastases in liver and lungs. In vitro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 activity. Macrophages exposed to ferumoxytol displayed increased mRNA associated with pro-inflammatory Th1-type responses. In vivo, ferumoxytol significantly inhibited growth of subcutaneous adenocarcinomas in mice. In addition, intravenous ferumoxytol treatment before intravenous tumour cell challenge prevented development of liver metastasis. Fluorescence-activated cell sorting (FACS) and histopathology studies showed that the observed tumour growth inhibition was accompanied by increased presence of pro-inflammatory M1 macrophages in the tumour tissues. Our results suggest that ferumoxytol could be applied {\^a} € off label' to protect the liver from metastatic seeds and potentiate macrophage-modulating cancer immunotherapies.",
author = "Saeid Zanganeh and Gregor Hutter and Ryan Spitler and Olga Lenkov and Morteza Mahmoudi and Aubie Shaw and Pajarinen, {Jukka Sakari} and Hossein Nejadnik and Stuart Goodman and Michael Moseley and Lisa Coussens and Daldrup-Link, {Heike Elisabeth}",
year = "2016",
month = "11",
day = "1",
doi = "10.1038/nnano.2016.168",
language = "English (US)",
volume = "11",
pages = "986--994",
journal = "Nature Nanotechnology",
issn = "1748-3387",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues

AU - Zanganeh, Saeid

AU - Hutter, Gregor

AU - Spitler, Ryan

AU - Lenkov, Olga

AU - Mahmoudi, Morteza

AU - Shaw, Aubie

AU - Pajarinen, Jukka Sakari

AU - Nejadnik, Hossein

AU - Goodman, Stuart

AU - Moseley, Michael

AU - Coussens, Lisa

AU - Daldrup-Link, Heike Elisabeth

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Until now, the Food and Drug Administration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been used for treating iron deficiency, as contrast agents for magnetic resonance imaging and as drug carriers. Here, we show an intrinsic therapeutic effect of ferumoxytol on the growth of early mammary cancers, and lung cancer metastases in liver and lungs. In vitro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 activity. Macrophages exposed to ferumoxytol displayed increased mRNA associated with pro-inflammatory Th1-type responses. In vivo, ferumoxytol significantly inhibited growth of subcutaneous adenocarcinomas in mice. In addition, intravenous ferumoxytol treatment before intravenous tumour cell challenge prevented development of liver metastasis. Fluorescence-activated cell sorting (FACS) and histopathology studies showed that the observed tumour growth inhibition was accompanied by increased presence of pro-inflammatory M1 macrophages in the tumour tissues. Our results suggest that ferumoxytol could be applied â € off label' to protect the liver from metastatic seeds and potentiate macrophage-modulating cancer immunotherapies.

AB - Until now, the Food and Drug Administration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been used for treating iron deficiency, as contrast agents for magnetic resonance imaging and as drug carriers. Here, we show an intrinsic therapeutic effect of ferumoxytol on the growth of early mammary cancers, and lung cancer metastases in liver and lungs. In vitro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 activity. Macrophages exposed to ferumoxytol displayed increased mRNA associated with pro-inflammatory Th1-type responses. In vivo, ferumoxytol significantly inhibited growth of subcutaneous adenocarcinomas in mice. In addition, intravenous ferumoxytol treatment before intravenous tumour cell challenge prevented development of liver metastasis. Fluorescence-activated cell sorting (FACS) and histopathology studies showed that the observed tumour growth inhibition was accompanied by increased presence of pro-inflammatory M1 macrophages in the tumour tissues. Our results suggest that ferumoxytol could be applied â € off label' to protect the liver from metastatic seeds and potentiate macrophage-modulating cancer immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=84988694000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988694000&partnerID=8YFLogxK

U2 - 10.1038/nnano.2016.168

DO - 10.1038/nnano.2016.168

M3 - Article

C2 - 27668795

AN - SCOPUS:84988694000

VL - 11

SP - 986

EP - 994

JO - Nature Nanotechnology

JF - Nature Nanotechnology

SN - 1748-3387

IS - 11

ER -